Leukemia & Lymphoma最新文献

Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study. 皮下达拉单抗联合卡非佐米和地塞米松（D-Kd）与卡非佐米和地塞米松（Kd）治疗复发/难治性多发性骨髓瘤患者：LYNX研究

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-03 DOI: 10.1080/10428194.2025.2561117

Nizar J Bahlis, Jeffrey Zonder, Lionel Karlin, Torben Plesner, Laura Paris, Tomasz Wrobel, Vania Hungria, Britta Besemer, Edvan Crusoe, Trine Silkjaer, Aurore Perrot, Philippe Moreau, Ka Lung Wu, Sosana Delimpasi, Meletios A Dimopoulos, Mark-David Levin, Silvia Mangiacavalli, Ivo Nnane, Yu Jin Kim, Maria Krevvata, Linlin Sha, Susan Wroblewski, Alba Tuozzo, Robin Carson, Thierry Facon

{"title":"Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.","authors":"Nizar J Bahlis, Jeffrey Zonder, Lionel Karlin, Torben Plesner, Laura Paris, Tomasz Wrobel, Vania Hungria, Britta Besemer, Edvan Crusoe, Trine Silkjaer, Aurore Perrot, Philippe Moreau, Ka Lung Wu, Sosana Delimpasi, Meletios A Dimopoulos, Mark-David Levin, Silvia Mangiacavalli, Ivo Nnane, Yu Jin Kim, Maria Krevvata, Linlin Sha, Susan Wroblewski, Alba Tuozzo, Robin Carson, Thierry Facon","doi":"10.1080/10428194.2025.2561117","DOIUrl":"https://doi.org/10.1080/10428194.2025.2561117","url":null,"abstract":"Daratumumab-based regimens demonstrate clinical efficacy in relapsed/refractory multiple myeloma (RRMM). As more patients receive frontline daratumumab-based therapy, evaluation of daratumumab retreatment is needed. In the phase 2 LYNX study (ClinicalTrials.gov Identifier: NCT03871829), 88 patients with RRMM who received 1-3 prior lines of therapy, one of which contained daratumumab, were randomized to receive subcutaneous daratumumab plus carfilzomib/dexamethasone (D-Kd; n = 44) or carfilzomib/dexamethasone (Kd; n = 44). The primary endpoint was the very good partial response or better (≥VGPR) rate. At the interim futility analysis, no significant differences in ≥ VGPR rates were found between treatment groups; therefore, the null hypothesis of no treatment difference was accepted, leading to study termination. At the final analysis, 45.5% of D-Kd patients and 40.9% of Kd patients achieved ≥ VGPR (odds ratio, 1.2 [90% CI, 0.59-2.46]; p = 0.6757). No new safety concerns were identified. Future studies are needed to optimize daratumumab-based regimens for patients with RRMM who have prior daratumumab exposure.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145213017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data. 在美国，FLT3抑制剂作为AML患者同种异体hct后维持治疗的现实治疗依从性和持久性：一项使用行政索赔数据的队列研究。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-03 DOI: 10.1080/10428194.2025.2561737

Vanessa E Kennedy, Maelys Touya, James Spalding, Christopher Young, Lingtao Frank Cao, David Nimke, Alana Block, Priti Pednekar

{"title":"Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data.","authors":"Vanessa E Kennedy, Maelys Touya, James Spalding, Christopher Young, Lingtao Frank Cao, David Nimke, Alana Block, Priti Pednekar","doi":"10.1080/10428194.2025.2561737","DOIUrl":"https://doi.org/10.1080/10428194.2025.2561737","url":null,"abstract":"In FLT3-mutated (FLT3mut+) acute myeloid leukemia (AML), relapse after allogeneic hematopoietic cell transplantation (alloHCT) is the leading cause of treatment failure and mortality. We evaluated real-world adherence and persistence of FLT3-like-tyrosine kinase inhibitors as alloHCT maintenance in FLT3mut+ AML. Claims data were extracted from adults with AML with ≥1 alloHCT between January 2016 and June 2022 who received gilteritinib, midostaurin, or sorafenib as post-alloHCT maintenance. Adherence (PDC; days covered ≥80% during follow-up) and persistence (days receiving treatment without switch/gap >60 days) were assessed. Of 162 patients, 41, 53, and 68 received post-alloHCT gilteritinib, midostaurin, or sorafenib, respectively. Adherence was higher in patients with a history of relapsed/refractory disease before alloHCT (n = 106 [65.4%], p = .021). Although this study did not focus on outcomes, no significant differences in post-alloHCT relapse by PDC were found. Discontinuation risk was higher for midostaurin (HR = 2.79, p = .0005) and sorafenib (HR = 1.74, p = .046) versus gilteritinib in patients with Commercial insurance vs Medicare/Medicaid (HR = 1.68, p = .019).","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145213006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia. 扎鲁替尼与依鲁替尼治疗的患者的毒性、无进展生存期和生活质量：来自ALPINE研究的复发或难治性慢性淋巴细胞白血病的Q-TWiST分析。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-05-23 DOI: 10.1080/10428194.2025.2506501

Vincent Lévy, Tushar Srivastava, Raju Gautam, Shilpi Swami, Kaijun Wang, Keri Yang, Leyla Mohseninejad

{"title":"Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia.","authors":"Vincent Lévy, Tushar Srivastava, Raju Gautam, Shilpi Swami, Kaijun Wang, Keri Yang, Leyla Mohseninejad","doi":"10.1080/10428194.2025.2506501","DOIUrl":"10.1080/10428194.2025.2506501","url":null,"abstract":"Zanubrutinib demonstrated significantly longer progression-free survival versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in the ALPINE trial. This post-hoc analysis using ALPINE data aimed to understand the benefit-risk associated with zanubrutinib versus ibrutinib employing quality-adjusted time without symptoms/toxicity (Q-TWiST) methodology. Survival data were partitioned into 3 health-states: TOX (time with toxicity); TWiST (time without symptoms/toxicity); and REL (time after relapse). Q-TWiST was estimated as mean time in each health-state weighted by respective utility score. In the base case, comprising high-risk patients, mean durations (in months) for zanubrutinib versus ibrutinib were 11.54 versus 11.38 (TOX), 14.45 versus 11.09 (TWiST), and 1.70 versus 3.78 (REL). Mean duration of Q-TWiST was 21.07 (zanubrutinib) versus 18.67 months (ibrutinib; difference: 2.40 months; 95%CI: 1.9-2.9; p<.001). This analysis demonstrated a significant Q-TWiST gain for zanubrutinib versus ibrutinib in high-risk R/R CLL patients, providing valuable insights that may inform clinical decision-making.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1884-1892"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence of the modified staging system and comparative performance of IPSS and revised IPSS in a Single-Center Asian cohort with Waldenström macroglobulinemia. 改良的分期系统和IPSS与改良IPSS在亚洲单中心Waldenström巨球蛋白血症队列中的比较表现的证据。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-05-18 DOI: 10.1080/10428194.2025.2505705

Jia Chen, Jian Li, Dao-Bin Zhou, Xin-Xin Cao

{"title":"Evidence of the modified staging system and comparative performance of IPSS and revised IPSS in a Single-Center Asian cohort with Waldenström macroglobulinemia.","authors":"Jia Chen, Jian Li, Dao-Bin Zhou, Xin-Xin Cao","doi":"10.1080/10428194.2025.2505705","DOIUrl":"10.1080/10428194.2025.2505705","url":null,"abstract":"Waldenström macroglobulinemia (WM), a rare incurable low-grade B-cell lymphoma, exhibits heterogeneous survival outcomes. We evaluated the prognostic performance of a novel modified staging system of WM (MSS-WM) through comparison with existing models in a single-center cohort of 294 symptomatic WM patients. MSS-WM demonstrated significant stratification capacity (p < 0.0001), with 5-year overall survival rates of 89% (low-risk), 84% (low-intermediate), and 52% (intermediate/high-risk). All MSS-WM factors, including age, serum albumin, and LDH demonstrated independent prognostic impact. In addition, high beta-2 microglobulin level also showed negative prognostic impacts (p = 0.0002). While high concordance of MSS-WM and the revised IPSS (rIPSS-WM) was confirmed, the rIPSS-WM exhibited better predictive accuracy. However, MSS-WM's simplified structure enhances clinical utility, enabling rapid risk stratification: 89% 5-year survival in low-risk vs 52% in high-risk groups. This practical staging system requires no complex calculations, making it preferable for routine clinical implementation while maintaining comparable prognostic discrimination.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1922-1930"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Insights into the pathogenesis and biology of chronic lymphocytic leukemia through analysis of its B-cell receptor. 通过分析慢性淋巴细胞白血病的b细胞受体来了解其发病机制和生物学。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-06-10 DOI: 10.1080/10428194.2025.2513005

Maria Dampmann, Bastian von Tresckow, Hans Christian Reinhardt, Ralf Küppers, Julia von Tresckow

引用次数: 0

Treatment of RAS-associated leukoproliferative disease (RALD) and Rosai-Dorfman disease in a patient with KRAS mutation. KRAS突变患者ras相关白质增生性疾病（RALD）和Rosai-Dorfman病的治疗

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-05-29 DOI: 10.1080/10428194.2025.2512025

Roberta S Azevedo, Luis Fayad, Rashmi Kanagal-Shamanna, Sanam Loghavi, Shimin Hu, Carlos E Bueso-Ramos, Koji Sasaki, Tareq Abuasab, Fareed Khawaja, Hannah Goulart, Iman Abou Dalle, Gautam Borthakur, Naveen Pemmaraju

引用次数: 0

Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma. mosunetuzumab和CAR-T细胞治疗复发/难治性滤泡性淋巴瘤的成本效益

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-06-09 DOI: 10.1080/10428194.2025.2506498

Meng-Hsuan Lin, Jonathan Weiss, Tycel J Phillips, Dahlia Sano, Shannon A Carty, Ryan Wilcox, Monalisa Ghosh, Iman Ahmed, Victoria R Nachar, David Hutton, Yasmin H Karimi

引用次数: 0

Familial aspects of multiple myeloma and Waldenström macroglobulinemia: understanding the predisposition in relatives and the importance of early diagnosis. 多发性骨髓瘤和Waldenström巨球蛋白血症的家族性：了解亲属的易感性和早期诊断的重要性。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-06-13 DOI: 10.1080/10428194.2025.2516256

Neta Sternbach, Morie A Gertz

引用次数: 0

State-wise disparities and temporal trends in acute myeloid leukemia (AML) in the United States of America (USA). 美国急性髓性白血病（AML）的州际差异和时间趋势。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-10-01 Epub Date: 2025-06-20 DOI: 10.1080/10428194.2025.2515598

Rupayan Kundu, Kriti Soni, Rishabh Kundu, Sudipto Mukherjee

引用次数: 0

Diagnostic utility of plasma circulating tumor DNA (ctDNA) in primary large B-cell lymphoma of the central nervous system (PCNS-LBCL): A paradigm shift? 血浆循环肿瘤DNA （ctDNA）在原发性中枢神经系统大b细胞淋巴瘤（PCNS-LBCL）中的诊断价值：范式转变？